latest news releases from the newsroom
IsoRay, Inc. Announces New Trading Symbol 'ISRY'
RICHLAND, Wash., Aug. 17, 2005 (PRIMEZONE) -- IsoRay, Inc. (Pink Sheets:ISRY) today announced that it has been assigned a new trading symbol following the closing of its recent merger with IsoRay Medical, Inc., which resulted in the name of the company changing from Century Park Pictures Corporation to IsoRay, Inc. Effective at the opening of the market on August 17, 2005, the new trading symbol for IsoRay, Inc. on the Pink Sheets will be ISRY.
NYMEX Europe Limited selects OMX for IT infrastructure in London
STOCKHOLM, Sweden, Aug. 17, 2005 (PRIMEZONE) -- NYMEX Europe Limited has signed a five-year agreement with OMX for IT infrastructure services for the open outcry futures exchange it plans to open in London. This agreement, which follows an earlier decision by NYMEX Europe to lease space in OMX's London office, includes hosting its European IT infrastructure as well as desktop and network support for its trading floor.
Fortis Finalizes Acquisition Price for Disbank
BRUSSELS, Belgium, Aug. 17, 2005 (PRIMEZONE) -- At the time of the announcement of the Fortis' execution of a Share Sale and Purchase Agreement (the "Agreement") with Dogan Sirketler Grubu Holding A.S. and certain other sellers for acquiring a 89.34% stake in Disbank (12 April 2005), Fortis had stated that final purchase price would be determined by way of considering the difference in the net asset value as stated in the Disbank's audited financial accounts for the period ending 31 May 2005 and the 31 December 2004 audited financial account. The parties have, on this basis, entered into negotiations for determining the final purchase price in accordance with the price adjustment mechanism stipulated in the Agreement.
Antisoma Granted U.S. Orphan Drug Status for AS1411 in Renal Cancer
LONDON, Aug. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) has received notification from the U.S. Food and Drug Administration (FDA) that its aptamer drug AS1411 has been granted Orphan Drug Designation in the U.S. for the treatment of renal cancer. This provides Antisoma with a seven-year period of market exclusivity if AS1411 gains marketing approval for the treatment of renal cancer in the U.S. AS1411 already has Orphan Drug Designation in the U.S. for the treatment of pancreatic cancer.